Renan Magalhães Montenegro Junior

Prof. Dr. Renan Magalhães Montenegro Junior

Universidade Federal do Ceará, Fortaleza, Ceará, Brazil
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2015 in BMC Public Health
Verified
Journal Article
Open access
PDF file
KBKatia Vergetti Bloch
Katia Vergetti Bloch
MSMoyses Szklo
Moyses Szklo
MKMaria Cristina C Kuschnir
Maria Cristina C Kuschnir
GAGabriela de Azevedo Abreu
Gabriela de Azevedo Abreu
LBLaura Augusta Barufaldi
Laura Augusta Barufaldi
TSThiago Luiz Nogueira da Silva
Thiago Luiz Nogueira da Silva
The Study of Cardiovascular Risk in Adolescents (Portuguese acronym, “ERICA”) is a multicenter, school-based country-wide cross-sectional study funded by the Brazilian Ministry of Health, which aims at estimating the prevalence of cardiovascular risk factors, including those included in the definition of the metabolic syndrome, in a random sample of adolescents aged 12 to 17 years in Brazilian cities with more than 100,000 inhabitants. Approximately 85,000 students were assessed in public and private schools. Brazil is a continental country with a heterogeneous population of 190 million living in its five main geographic regions (North, Northeast, Midwest, South and Southeast). ERICA is a pioneering study that will assess the prevalence rates of cardiovascular risk factors in Brazilian adolescents using a sample with national and regional representativeness. This paper describes the rationale, design and procedures of ERICA. Participants answered a self-administered questionnaire using an electronic device, in order to obtain information on demographic and lifestyle characteristics, including physical activity, smoking, alcohol intake, sleeping hours, common mental disorders and reproductive and oral health. Dietary intake was assessed using a 24-hour dietary recall. Anthropometric measures (weight, height and waist circumference) and blood pressure were also be measured. Blood was collected from a subsample of approximately 44,000 adolescents for measurements of fasting glucose, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, glycated hemoglobin and fasting insulin. The study findings will be instrumental to the development of public policies aiming at the prevention of obesity, atherosclerotic diseases and diabetes in an adolescent population.

27 May 2020 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
LMLuizianne Mariano Martins
Luizianne Mariano Martins
VFVirgínia Oliveira Fernandes
Virgínia Oliveira Fernandes
MCManuela Montenegro Dias de Carvalho
Manuela Montenegro Dias de Carvalho
DGDaniel Duarte Gadelha
Daniel Duarte Gadelha
PQPaulo Cruz de Queiroz
Paulo Cruz de Queiroz
Renan Magalhães Montenegro JuniorRenan Magalhães Montenegro Junior
Renan Magalhães Montenegro Junior
A literature review on the clinical, laboratory, and treatment features of type B insulin resistance syndrome (TBIRS). Data from PubMed, the Virtual Health Library and Cochrane database were selected and analyzed using the REDCap application and R statistical program. From 182 papers, 65 were selected, which assessed 119 clinical cases, 76.5% in females and 42.9% in African-Americans, with an average age of 44 years. A common feature of TBIRS is co-occurrence of autoimmune diseases, such as systemic lupus erythematosus (most frequently reported). Hyperglycemia of difficult control was the mostly reported condition. Tests for anti-insulin receptor antibodies were positive in 44.2% of the cases. Disease management comprised fractional diet, insulin therapy (maximum dose given was 57 600 IU/day), plasmapheresis and immunosuppression with several classes of drugs, mainly glucocorticoids. Remission occurred in 69.7% of cases, in 30.3% of these spontaneously. The mortality rate was 15.38%. There was an inverse relationship between anti-insulin antibodies and remission (p = 0.033); and a positive correlation between combined immunosuppressive therapy and remission (p = 0.002). Relapse occurred in 7.6% of the cases. This rare syndrome has difficult-to-control diabetes, even with high doses of insulin, and it is usually associated with autoimmune diseases. Therapeutic advances using immunomodulatory therapy have led to significant improvements in the rate of remission.

13 April 2018 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
FBFrancisca Kalline de Almeida Barreto
Francisca Kalline de Almeida Barreto
Renan Magalhães Montenegro JuniorRenan Magalhães Montenegro Junior
Renan Magalhães Montenegro Junior
VFVirginia Oliveira Fernandes
Virginia Oliveira Fernandes
RORhaquel Oliveira
Rhaquel Oliveira
LBLívia Aline de Araújo Batista
Lívia Aline de Araújo Batista
Luciano Pamplona de Góes CAVALCANTILuciano Pamplona de Góes CAVALCANTI
Luciano Pamplona de Góes CAVALCANTI
Chikungunya (CHIK) is a viral disease transmitted by mosquitoes. The first cases in Brazil were confirmed in 2014. Between 2016 and 2017, over 300,000 cases were identified during this period, with nearly 300 deaths. The clinical manifestations, pathogenesis and risk factors for occurrence of severe cases are not yet well understood, although it is known that the severity of the cases is associated with the presence of comorbidities, especially diabetes mellitus (DM). To review the medical literature for the associations between DM and CHIK and to understand the potential impact on metabolic state and its complications. Literature review was carried out to search for articles (English, Portuguese and Spanish) in Medline and Virtual Health Library databases for the period between 1952 and 2017, with the following keywords: “Chikungunya fever”, “Chikungunya virus”, “diabetes mellitus”, “diabetes”, “diabetes complications “and “multi-morbidities (MeSH) “with interposition of the Boolean operator “AND”. After removal of duplicities and following exclusion criteria, 11 articles were selected. Our results showed that the patients of CHIK with DM had more severe and prolonged symptoms of CHIK and more frequently required hospitalization. No study investigated the biological process to explain how hyperglycemic state worsened the clinical manifestations of Chikungunya in diabetic patients. An important association between DM and the severity of CHIK is observed. Prospective and more rigorous controlled studies are required to generate evidence that might y elucidate the causes of this relationship. Given the fast expanding viral infection of Chikungunya in Central and South America, Asia and Africa in recent years in the context of exponential increase in diabetes globally, the issue deserves global attention.

1 February 2021 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
JPJaquellyne Gurgel Penaforte-Saboia
Jaquellyne Gurgel Penaforte-Saboia
CCCarlos Eduardo Barra Couri
Carlos Eduardo Barra Couri
NANatasha Vasconcelos Albuquerque
Natasha Vasconcelos Albuquerque
VSVanessa Lauanna Lima Silva
Vanessa Lauanna Lima Silva
NONatália Bitar da Cunha Olegario
Natália Bitar da Cunha Olegario
Renan Magalhães Montenegro JuniorRenan Magalhães Montenegro Junior
Renan Magalhães Montenegro Junior
Type 1 diabetes mellitus (T1DM) results from the immune cell-mediated destruction of functional pancreatic β-cells. In the presymptomatic period, T1DM is characterized by the presence of two or more autoantibodies against the islet cells in patients without glycemic decompensation. Therapeutic strategies that can modify the autoimmune process could slow the progression of T1DM. Dipeptidyl peptidase-4 (DPP-4) or CD26, a multifunctional serine protease with a dual function (regulatory protease and binding protein), can modulate inflammation and immune cell-mediated β-cell destruction. CD26 is involved in T-cell co-stimulation, migration, memory development, thymic maturation, and emigration patterns. DPP-4 degrades the peptide hormones GLP-1 and GIP. In addition to regulating glucose metabolism, DPP-4 exerts anti-apoptotic, regenerative, and proliferative effects to promote β-cell mass expansion. GLP-1 receptor signaling may regulate murine lymphocyte proliferation and maintenance of peripheral regulatory T-cells. In patients with T1DM, the serum DPP-4 activity is upregulated. Several studies have suggested that the upregulated DPP-4 activity is correlated with T1DM pathophysiology. DPP-4, which is preferentially expressed on the Th1 surface, can promote the polarization of Th1 immunity, a prerequisite for T1DM development. CD26 inhibition can suppress T-cell proliferation and Th1 cytokine production and stimulate tumor growth factor beta-1 (TGF-β 1) secretion, which plays an important role in the regulation of autoimmunity in T1DM. Studies on humans or animal models of T1DM have suggested that DPP-4 inhibitors can improve β-cell function and attenuate autoimmunity in addition to decreasing insulin dependence. This review summarizes the emerging roles of DPP-4 inhibitors in potentially delaying the progression of T1DM.

1 June 2018 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
VOValzimeire Do Nascimento de Oliveira
Valzimeire Do Nascimento de Oliveira
ANAbelardo Barbosa Moreira Lima Neto
Abelardo Barbosa Moreira Lima Neto
MTMaurício Fraga van Tilburg
Maurício Fraga van Tilburg
AMAna Cristina de Oliveira Monteiro-Moreira
Ana Cristina de Oliveira Monteiro-Moreira
MLMarina Duarte Pinto Lobo
Marina Duarte Pinto Lobo
MGMaria Izabel Florindo Guedes
Maria Izabel Florindo Guedes
Purpose: Type 1 diabetes mellitus (DM1) is one of the most common chronic diseases observed during childhood. The incidence of DM1 is increasing worldwide, and there is currently no way to prevent or delay the onset or to cure the disease. Most diseases, including diabetes, stem from abnormalities in the functioning of proteins, and some studies have reported the expression of protein variation to be involved in the development of DM1. Thus, the aim of this study was to investigate the differential expression of serum proteins in patients with DM1.
Materials and methods:
Serum of patients with DM1 (n=30) and healthy controls (n=30) was collected. A proteomic approach was used with depletion of albumin and immunoglobulin G chromatography on serum samples followed by data-independent, label-free mass spectrometric analysis. Results: A total of eight serum proteins were identified as being differentially expressed and involved in the immune system, lipid metabolism, and pathways of coagulation. DM1 was associated with the upregulation of six proteins: alpha-2-macroglobulin, apolipoprotein A-II, β2 glycoprotein I, Ig alpha-2 chain C region, alpha-1-microglobulin, and prothrombin. A total of two proteins were downregulated, including pregnancy zone protein and complement C4. Conclusion: To the best of our knowledge, these findings show differential expression of proteins revealing new proteins that may be involved in the development and progression of diabetes.

20 August 2018 in Frontiers in Endocrinology
Verified
Journal Article
Open access
Renan Magalhães Montenegro JuniorRenan Magalhães Montenegro Junior
Renan Magalhães Montenegro Junior
ACAline Dantas Costa-Riquetto
Aline Dantas Costa-Riquetto
VFVirgínia Oliveira Fernandes
Virgínia Oliveira Fernandes
AMAna Paula Dias Rangel Montenegro
Ana Paula Dias Rangel Montenegro
LSLucas Santos de Santana
Lucas Santos de Santana
CDCatarina Brasil D'ALva
Catarina Brasil D'ALva
Background. Dunnigan-type familial partial lipodystrophy, a rare autosomal dominant disease caused by heterozygous missense mutations in LMNA gene presents regional loss of subcutaneous adipose tissue from puberty. But the same mutation may present huge clinical heterogeneity. Methods. We report 4 patients from the same family with p.R582C LMNA mutation, 3 of them with homozygous and 1 with heterozygous state, presenting 3 distinct lipodystrophic phenotypes and we compare their clinical and metabolic features. Results. Case descriptions: The proband: a 12 year-old girl who developed selective loss of subcutaneous fat and hypertriglyceridemia, was diagnosed with lipodystrophy. In adult life, she presented severe subcutaneous fat atrophy in limbs and abdomen with a remarkable dorsocervical fat accumulation, and diabetes at age 23 (BMI 20.5 Kg/m²). Proband’s sister: phenotypically normal 8 year-old girl with hypertriglyceridemia who developed progressive features of partial lipodystrophy from 11 years-old and diabetes at age 22 (BMI 20.7 Kg/m²). Proband’s mother: at age 32 revealed a severe generalized lipodystrophic phenotype (BMI 17.2 Kg/m²) and she developed diabetes at age 24, kidney failure at age 41 and deceased at 42 years-old due to diabetic complications. Proband´s father: 50 years-old man with abdominal fat concentration without lipoatrophy (BMI 24.9 Kg/m²). The family´s molecular study, by massively parallel sequencing using a plataform of genes related to genetic lipodystrophies, followed by Sanger sequencing, revealed the transversion c.1744C>T at exon 11 of the LMNA gene (p.R582C) in homozygous state (mother and daughters) and in heterozygous state (father). Conclusion. The p.R582C LMNA mutation in heterozygous resulted in an uncertain phenotype and in homozygous caused severe lipodystrophic syndromes with phenotypic differences, as the finding of partial or generalized lipodystophy. That familial lipodystrophy linked to mutations in this gene is a disease of great clinical heterogeneity.